Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y7IU
|
|||
| Former ID |
DAP000320
|
|||
| Drug Name |
Budesonide
|
|||
| Synonyms |
Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Approved | [1], [2] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H34O6
|
|||
| Canonical SMILES |
CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C
|
|||
| InChI |
1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
|
|||
| InChIKey |
VOVIALXJUBGFJZ-KWVAZRHASA-N
|
|||
| CAS Number |
CAS 51333-22-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855541, 7847312, 7978823, 8616471, 10321783, 11466546, 11467666, 11486132, 11528595, 12013315, 14807548, 14929955, 17404737, 24278277, 39289945, 46504869, 47646553, 47720602, 47869643, 47943751, 48169361, 49698535, 50105232, 53777280, 53789711, 56394980, 56422168, 57357962, 77787022, 81092787, 85787937, 90341081, 90473637, 92125441, 92303636, 92721807, 93576669, 103455384, 103914268, 104170124, 121360873, 121362487, 121363112, 124749512, 124800069, 124886759, 126627527, 126651544, 127278596, 127278597
|
|||
| ChEBI ID |
CHEBI:3207
|
|||
| ADReCS Drug ID | BADD_D00306 | |||
| SuperDrug ATC ID |
A07EA06; D07AC09; R01AD05; R03BA02
|
|||
| SuperDrug CAS ID |
cas=051333223
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.716; p = 0.005). | |||
|
Studied Microbe: Bacteroides eggerthii DSM20697
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides eggerthii DSM20697 (log2FC = -0.394; p = 0.045). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.669; p = 0.011). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.652; p = 0.028). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.606; p = 0.033). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.425; p = 0.009). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.442; p = 0.004). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.666; p = 0.039). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Odoribacter splanchnicus (log2FC = -0.512; p = 0.006). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.334; p = 0.016). | |||
|
Studied Microbe: Parabacteroides johnsonii DSM 18315
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Parabacteroides johnsonii DSM 18315 (log2FC = -0.372; p = 0.012). | |||
|
Studied Microbe: Parabacteroides merdae ATCC 43184
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Parabacteroides merdae ATCC 43184 (log2FC = -0.349; p = 0.024). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Eubacterium biforme DSM 3989
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Eubacterium biforme DSM 3989 (log2FC = -0.997; p = 0.021). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.429; p = 0.02). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Budesonide can be metabolized by Clostridium sp. (log2FC = -0.408; p = 0.026). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Antagonist | [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class II | ||||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Regulation of Androgen receptor activity | ||||
| AP-1 transcription factor network | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| SIDS Susceptibility Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Endoderm Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7434). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. | |||
| REF 5 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.